Cardioprotective effects of deferoxamine in acute and subacute cardiotoxicities of doxorubicin: a randomized clinical trial

The Egyptian Heart Journal

Table 4 Tissue Doppler echocardiography parameters in the study patients

Parameters	Mean ± SD			P-value			ANOVA
Parameters	Group 1 (n = 20)	Group 2 (n = 20)	Group 3 (n = 20)	Groups1 & 2	Groups2 & 3	Groups1 & 3	ANOVA
SM	11.73 ± 6.22	8.64 ± 1.48	9.22 ± 3.4	0.082	0.592	0.195	0.151
EaM	14.54 ± 4.45	16.35 ± 4.04	10.42 ± 12.61	0.286	0.116	0.265	0.173
AaM	7.42 ± 7.41	9.10 ± 4.33	7.02 ± 6.71	0.500	0.365	0.884	0.685
SS	10.30 ± 3.37	8.93 ± 1.74	8.71 ± 2.1	0.217	0.772	0.144	0.214
EaS	11.45 ± 2.97	12.39 ± 7.52	10.07 ± 7.67	0.691	0.445	0.496	0.637
AaS	95.22 ± 307.6	8.09 ± 5.02	7.92 ± 5.18	0.338	0.933	0.326	0.362
ST	16.42 ± 4.73	14.02 ± 2.7	17.98 ± 18.7	0.134	0.475	0.756	0.678
EaT	15.00 ± 4.37	17.84 ± 4.58	15.66 ± 9.17	0.113	0.463	0.804	0.512
AaT	16.45 ± 4.73	13.85 ± 7.00	10.86 ± 7.57	0.285	0.316	0.035	0.107
EM/EaM	8.14 ± 4.78	7.13 ± 2.49	5.35 ± 5.38	0.514	0.304	0.151	0.254

Group 1: control group; group 2: intervention with deferoxamine 10-times the doxorubicin dose; group 3: intervention with deferoxamine 50 mg/kg
SM tissue Doppler systolic velocity of mitral valve, EaM early diastolic velocity at lateral annulus of mitral valve, AaM late diastolic velocity at lateral annulus of mitral valve, SS systolic velocity of septum, EaS early diastolic velocity of septum, AaS late diastolic velocity of septum, ST systolic velocity of tricuspid valve, EaT early diastolic velocity at lateral annulus of tricuspid valve, AaT late diastolic velocity at lateral annulus of tricuspid valve, EM/EaM early diastolic velocity of mitral to early diastolic velocity at lateral annulus of mitral valve